Established strategic plan to become the preferred drug delivery partner for specific infusion therapies in select markets
Net Revenue increased 12.4% to $17.4 million from $15.4 million
Adjusted EBITDA* expanded to $2.7 million, up 73.9% from $1.6 million in 2017
This presentation contains forward looking statements that involve risks and uncertainties, including but not limited to those related to our ability to achieve the goals and targets set forth in our Strategic Plan and the addressable market for our products. Actual results and events may differ significantly from results and events discussed in the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, the following: introduction of competitive products; availability of insurance reimbursement; changes in U.S. Food and Drug Administration regulations; changes to health care policies; success of our research and development efforts; our ability to raise capital if or when needed; acceptance of and demand for new and existing products; expanded market acceptance of the FREEDOM System; our ability to obtain required governmental approvals; success in enforcing and obtaining patents; continued performance by principal suppliers; continued customer preference to work through distributors; continued service of key personnel and attracting and maintaining new personnel; the costs, duration and ultimate outcome of litigation; and general economic and business conditions. We undertake no obligation to update publicly this presentation or any forwardlooking statements to reflect new information, events, or circumstances after the hereof.